| Literature DB >> 32337223 |
Jannan Ghapanchi1, Zahra Ranjbar1, Mohammad Javad Mokhtari2, Fatemeh Koohpeima3, Maryam Derakhshan3, Bijan Khademi4, Hamid Ghaderi5, Shamsoddinali Sheikhbahaei6, Ehsan Aliabadi7.
Abstract
Lack of protein-coding capacity is a main characteristic of long noncoding RNAs (lncRNAs) which, as molecular biomarkers, have found a novel pharmacological application in cancer and are reported to be important regulators of gene expression. H19 is reportedly involved in cancer progression and tumorigenesis. One of the most common types of head and neck cancers is oral squamous cell carcinoma (OSCC). The main objective of the present study was to evaluate the correlation of OSCC susceptibility with H19 gene in an Iranian population. This research was performed on 400 subjects of both sexes referred to the Namazi Hospital affiliated with the Shiraz University of Medical Sciences (SUMS). Individuals aged 15-88 years were divided into two groups: pathologically diagnosed patients with new-onset OSCC and healthy controls. After written and informed consent was obtained from the individuals, genomic DNA was extracted. The tetra-primer ARMS-PCR technique was performed for DNA genotyping by the use of specific primer pairs. The susceptibility of OSCC and H19 gene polymorphism sites was further analyzed (rs217727 and rs2107425). The allele and genotype frequencies of H19 rs2107425 polymorphism were similar between OSCC cases and controls. The H19 rs217727T allele frequency was significantly higher in OSCC cases (P = 0.002), and the polymorphism of H19 rs217727 was associated with OSCC susceptibility in the codominant (OR = 6.04, 95%CI = 1.70 - 21.42, P = 0.001 for TT genotype), dominant (OR = 1.62, 95%CI = 1.08 - 2.43, P = 0.01), and recessive (OR = 5.32, 95%CI = 1.51 - 18.69, P = 0.003) models. This study showed that rs217727 and OSCC susceptibility were statistically correlated in the Iranian population.Entities:
Year: 2020 PMID: 32337223 PMCID: PMC7154967 DOI: 10.1155/2020/1634252
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographic characteristics of the sample.
| Characteristics | Control (%) | Case (%) |
|---|---|---|
| Number | 200 (100) | 200 (100) |
| Males | 156 (78) | 156 (78) |
| Females | 44 (22) | 44 (22) |
| Age | 55.21 ± 9.45 | 59.69 ± 16.24 |
Patient inclusion and exclusion criteria.
| Criteria | Description |
|---|---|
| Inclusion | (i) Histologically proven squamous cell carcinoma of the oral cavity |
|
| |
| Exclusion | (i) Distant metastasis |
The primers used for detection of rs217727 and rs2107425 polymorphisms in lncRNA H19 gene.
| Gene polymorphisms | Chr:position | Product size | Primers | Sequence (5′ to 3′) |
|---|---|---|---|---|
| rs217727 | Chr11:1995678 | Outer primers: 397 bp | FO | ATGACTCAGGAATCGGCTCTGGAAGGTG |
| RO | GGGGAAACAGAGTCGTGGAGGCTTTGA | |||
| C allele: 248 bp | FI | TCATCTTCATGGCCACCCCCTGCTGT | ||
| T allele: 200 bp | RI | ATATGGTGGCTGGTGGTCAACCGTACG | ||
|
| ||||
| rs2107425 | Chr11:1999845 | Outer primers: 266 bp | FO | ACTTGAGTCCCAGGCCATGACACTGAAG |
| RO | CGGAATTGGTTGTAGTTGTGGAATCGGA | |||
| T allele: 195 bp | FI | CGACCTGAAGATCTGGTGCGGCTACT | ||
| C allele: 124 bp | RI | GGGTCATCTGGGAATAGGACACTCCTG | ||
The alleles and genotypes frequency of the H19 polymorphisms in OSCC cases and healthy Controls.
| Polymorphisms | Alleles |
|
| Genotypes |
|
|
| |||
|---|---|---|---|---|---|---|---|---|---|---|
| rs217727 | C | T | CC | CT | TT | |||||
| Case | 295 (73.75) | 105 (26.25) | 8.96 | 0.002 | 110 (55) | 75 (37.5) | 15 (7.5) | 11.05 | 0.004 | 0.65 |
| Control | 330 (82.5) | 70 (17.5) | 133 (66.5) | 64 (32) | 3 (1.5) | |||||
| rs2107425 | ||||||||||
| Case | 252 (63) | 148 (37) | 0.04 | 0.8 | 79 (39.5) | 94 (47) | 27 (13.5) | 0.49 | 0.78 | 0.90 |
| Control | 249 (62.25) | 151 (37.75) | 74 (37) | 101 (50.5) | 25 (12.5) | |||||
HWE, Hardy–Weinberg equilibrium.
The association of H19 polymorphism and OSCC susceptibility.
| Inheritance model | Genotype | Cases | Controls | OR (95% CI) |
| |
|---|---|---|---|---|---|---|
| rs217727 | Codominanta | CC | 110 (55) | 133 (66.5) | ||
| CT | 75 (37.5) | 64 (32) | 1.47 (0.93-2.15) | 0.10 | ||
| TT | 15 (7.5) | 3 (1.5) | 6.04 (1.70-21.42) | 0.001 | ||
| Dominantb | CC | 110 (55) | 133 (66.5) | |||
| CT+TT | 90 (45) | 67 (33.5) | 1.62 (1.08-2.43) | 0.01 | ||
| Recessivec | CC+CT | 185 (92.5) | 197 (98.5) | |||
| TT | 15 (7.5) | 3 (1.5) | 5.32 (1.51-18.69) | 0.003 | ||
| Overdominantd | CC+TT | 125 (62.5) | 136 (68) | |||
| CT | 75 (37.5) | 64 (32) | 1.27 (0.84-1.92) | 0.24 | ||
|
| ||||||
| rs2107425 | Codominant | CC | 79 (39.5) | 74 (37) | ||
| CT | 94 (47) | 101 (50.5) | 0.87 (0.57-1.33) | 0.52 | ||
| TT | 27 (13.5) | 25 (12.5) | 1.01 (0.53-1.89) | 0.97 | ||
| Dominant | CC | 79 (39.5) | 74 (37) | |||
| CT+TT | 121 (60.5) | 126 (63) | 0.89 (0.60-1.34) | 0.60 | ||
| Recessive | CC+CT | 173 (86.5) | 175 (87.5) | |||
| TT | 27 (13.5) | 25 (12.5) | 1.09 (0.60-1.95) | 0.76 | ||
| Overdominant | CC+TT | 106 (53) | 99 (49.5) | |||
| CT | 94 (47) | 101 (50.5) | 0.86 (0.58-1.28) | 0.48 | ||
OR, odd ratio; CI, confidence interval. aCodominant, major allele homozygotes vs. heterozygotes. bDominant, major allele homozygotes vs. heterozygotes + minor allele homozygotes. cRecessive, major allele homozygotes + heterozygotes vs. minor allele homozygotes. dOverdominant, major allele homozygotes + minor allele homozygotes vs. heterozygotes.